CTNM
Contineum Therapeutics Inc. - Ordinary Shares - Class A

145
Mkt Cap
$416.07M
Volume
213,220.00
52W High
$15.25
52W Low
$3.35
PE Ratio
-5.05
CTNM Fundamentals
Price
$11.39
Prev Close
$11.43
Open
$11.38
50D MA
$11.35
Beta
0.46
Avg. Volume
252,150.82
EPS (Annual)
-$1.63
P/B
1.84
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock?
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·4d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.5% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·4d ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Raised to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Contineum Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·15d ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered shares of Contineum Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·23d ago
News Placeholder
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight analysts that are currently covering the stock...
MarketBeat·24d ago
News Placeholder
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·24d ago
News Placeholder
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·24d ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Price Target Cut to $22.00 by Analysts at Royal Bank Of Canada
Royal Bank Of Canada lowered their target price on Contineum Therapeutics from $25.00 to $22.00 and set an "outperform" rating for the company in a research note on Friday...
MarketBeat·1mo ago
News Placeholder
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·2mo ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Coverage Initiated at Leerink Partners
Leerink Partners initiated coverage on shares of Contineum Therapeutics in a report on Thursday. They issued an "outperform" rating and a $22.00 price objective on the stock...
MarketBeat·2mo ago
<
1
2
...
>

Latest CTNM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.